Data Rich, Information Poor: Can We Use Electronic Health Records to Create a Learning Healthcare System for Pharmaceuticals?

被引:65
作者
Eichler, Hans-Georg [1 ]
Bloechl-Daum, Brigitte [2 ]
Broich, Karl [3 ]
Kyrle, Paul Alexander [2 ]
Oderkirk, Jillian [4 ]
Rasi, Guido [1 ]
Ivo, Rui Santos [5 ]
Schuurman, Ad [6 ]
Senderovitz, Thomas [7 ]
Slawomirski, Luke [4 ]
Wenzl, Martin [4 ]
Paris, Valerie [4 ]
机构
[1] European Med Agcy, London, England
[2] Med Univ Vienna, Vienna, Austria
[3] Fed Inst Drugs & Med Devices, Bonn, Germany
[4] Org Econ Cooperat & Dev, Paris, France
[5] Natl Author Med & Hlth Prod, Lisbon, Portugal
[6] Natl Hlth Care Inst, Diemen, Netherlands
[7] Danish Med Agcy, Copenhagen, Denmark
关键词
RISK-ASSESSMENT; RECURRENCE; DESIGN; TRIALS;
D O I
10.1002/cpt.1226
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Judicious use of real-world data (RWD) is expected to make all steps in the development and use of pharmaceuticals more effective and efficient, including research and development, regulatory decision making, health technology assessment, pricing, and reimbursement decisions and treatment. A "learning healthcare system" based on electronic health records and other routinely collected data will be required to harness the full potential of RWD to complement evidence based on randomized controlled trials. We describe and illustrate with examples the growing demand for a learning healthcare system; we contrast the exigencies of an efficient pharmaceutical ecosystem in the future with current deficiencies highlighted in recently published Organisation for Economic Co-operation and Development (OECD) reports; and we reflect on the steps necessary to enable the transition from healthcare data to actionable information. A coordinated effort from all stakeholders and international cooperation will be required to increase the speed of implementation of the learning healthcare system, to everybody's benefit.
引用
收藏
页码:912 / 922
页数:11
相关论文
共 39 条
[1]   Blockchain Technology Applications in Health Care [J].
Angraal, Suveen ;
Krumholz, Harlan M. ;
Schulz, Wade L. .
CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 2017, 10 (09)
[2]  
[Anonymous], 2017, The Next Production Revolution, DOI 10.1787/9789264271036-en
[3]  
[Anonymous], 2009, Beyond the HIPAA Privacy Rule: Enhancing Privacy, Improving Health Through Research
[4]   Proactively managing the risk of marketed drugs: experience with the EMA Pharmacovigilance Risk Assessment Committee [J].
Arlett, Peter ;
Portier, Geraldine ;
de Lisa, Roberto ;
Blake, Kevin ;
Wathion, Noel ;
Dogne, Jean-Michel ;
Spooner, Almath ;
Raine, June ;
Rasi, Guido .
NATURE REVIEWS DRUG DISCOVERY, 2014, 13 (05) :395-395
[5]   The European Medicines Agency's use of prioritised independent research for best evidence in regulatory action on diclofenac [J].
Arlett, Peter ;
Sarac, Sinan B. ;
Thomson, Andrew ;
Davies, Claire ;
Teixeira, Tania ;
Blake, Kevin V. ;
Stenver, Doris .
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2014, 23 (04) :431-434
[6]  
Black N, 1996, BRIT MED J, V312, P1215
[7]   Policies and strategies to facilitate secondary use of research data in the health sciences [J].
Burton, Paul R. ;
Banner, Natalie ;
Elliot, Mark J. ;
Knoppers, Bartha Maria ;
Banks, James .
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 2017, 46 (06) :1729-1733
[8]   Towards of a Business Intelligence Platform to Portuguese Misericordias [J].
Coelho, Danilo ;
Miranda, Joao ;
Portela, Filipe ;
Machado, Jose ;
Santos, Manuel Filipe ;
Abelha, Antonio .
INTERNATIONAL CONFERENCE ON ENTERPRISE INFORMATION SYSTEMS/INTERNATIONAL CONFERENCE ON PROJECT MANAGEMENT/INTERNATIONAL CONFERENCE ON HEALTH AND SOCIAL CARE INFORMATION SYSTEMS AND TECHNOLOGIES, CENTERIS/PROJMAN / HCIST 2016, 2016, 100 :762-767
[9]   From Famine to Feast: Developing Early-Phase Combination Immunotherapy Trials Wisely [J].
Day, Daphne ;
Monjazeb, Arta M. ;
Sharon, Elad ;
Ivy, S. Percy ;
Rubin, Eric H. ;
Rosner, Gary L. ;
Butler, Marcus O. .
CLINICAL CANCER RESEARCH, 2017, 23 (17) :4980-4991
[10]  
Department of Health and Health Consult, DEV FRAM SEC US MY H